Clinical Trial Update: GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for GRASPA (erythrocyte-encapsulated L-asparaginase) in relapsed acute lymphoblastic leukemia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• GRASPA (L-asparaginase encapsulated in red blood cells)

Snippet

Sponsor: ERYtech Pharma | Conditions: Acute Lymphoblastic Leukemia, in Relapse | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-02-02